Ali Abdelaal, MD
Hematology & Oncology · Harrison, ARNPI 1255344131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.9% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,635 and has fallen 98.1% since, to $32 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 262 payments — averaging $15.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$605
- Pfizer$469
- Incyte Corporation$405
- Exelixis Inc.$265
- AstraZeneca$224
- Sanofi$197
- plus $2K from 32 others
What the payments were for
- Consulting fees$2506%
- Food & beverage$3,75191%
- Education$1243%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 44 | $605 |
| Pfizer | 33 | $469 |
| Incyte Corporation | 11 | $405 |
| Exelixis Inc. | 17 | $265 |
| AstraZeneca | 13 | $224 |
| Sanofi | 14 | $197 |
| Genentech USA, Inc. | 13 | $194 |
| Novartis | 13 | $163 |
| Johnson & Johnson(2 entities) | 8 | $136 |
| Amgen | 9 | $130 |
| Seagen Inc. | 9 | $128 |
| Bristol Myers Squibb | 8 | $108 |
| Bayer | 6 | $99 |
| Regeneron Healthcare Solutions, Inc. | 6 | $97 |
| Eisai Inc. | 6 | $83 |
| Lilly USA, LLC | 5 | $75 |
| EMD Serono, Inc. | 5 | $71 |
| Daiichi Sankyo Inc. | 4 | $69 |
| AbbVie | 5 | $67 |
| Sobi, Inc | 3 | $52 |
| Ipsen Biopharmaceuticals, Inc | 3 | $51 |
| Puma Biotechnology, Inc. | 3 | $45 |
| Gilead | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Beigene USA, Inc. | 2 | $36 |
| Myriad Genetic Laboratories, Inc. | 1 | $35 |
| Tersera Therapeutics LLC | 1 | $34 |
| Pharmaessentia USA Corporation | 2 | $32 |
| Rigel Pharmaceuticals, Inc. | 2 | $31 |
| Foundation Medicine, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 2 | $24 |
| Boehringer Ingelheim | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| G1 Therapeutics, Inc. | 1 | $14 |
| Dova Pharmaceuticals | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $12 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
How this compares
$4,125 in reported general payments places this provider in the 45th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 28 | $404,515 |
| DopteletAvatrombopag Maleate | 27 | $392,251 |
| ImbruvicaIbrutinib | 12 | $198,153 |
| NubeqaDarolutamide | 12 | $166,147 |
| VenclextaVenetoclax | 11 | $159,065 |
| Anagrelide Hcl | 41 | $3,903 |
| Anastrozole | 163 | $2,117 |
| Letrozole | 76 | $929 |
| Hydroxyurea | 59 | $796 |
| Ondansetron OdtOndansetron | 23 | $725 |
| Ondansetron Hcl | 39 | $508 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $500 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $371 |
| Dexamethasone | 20 | $318 |
| Gabapentin | 20 | $133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $405 | $404,51528 claims |
| Dova PharmaceuticalsDoptelet | $13 | $392,25127 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $14 | $198,15312 claims |
| BayerNubeqa | $99 | $166,14712 claims |
| AbbVieVenclexta | $67 | $159,06511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Harrison
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
- Isam Abdel-KarimFort Smith$199K
- Appalanaidu SasapuLittle Rock$63K
- Stephan RosenfeldFayetteville$61K
- Stephen DiversHot Springs$55K
- Humdum DurraniFort Smith$54K
- Peter EmanuelLittle Rock$53K
- Patrick TravisFayetteville$37K
- Brad BaltzLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.